Literature DB >> 32540983

Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.

Teresa L Parsons1, Kevin N Gwenden1, Mark A Marzinke2,3.   

Abstract

Tenofovir (TFV) alafenamide fumarate (TAF) is an antiretroviral that has been evaluated in alternative drug delivery systems in several species. The ex vivo stability of TAF was evaluated, and TAF was stable in dog-, sheep-, and macaque-spiked plasma. A negative bias was observed in TAF recovery in rabbit-spiked plasma; there was complete loss of TAF and corresponding overestimation of TFV in rodent-spiked plasma. These data highlight considerations when evaluating TAF and TFV concentrations in preclinical studies.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  HIV; TAF; hydrolysis; pharmacology; tenofovir alafenamide fumarate

Mesh：

Substances：

Year:  2020        PMID： 32540983      PMCID： PMC7449208          DOI： 10.1128/AAC.00930-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

Authors:  Edwin DeJesus; Bernard Haas; Sorana Segal-Maurer; Moti N Ramgopal; Anthony Mills; Nicolas Margot; Ya-Pei Liu; Tariro Makadzange; Scott McCallister
Journal:  AIDS Res Hum Retroviruses       Date:  2018-03-20       Impact factor: 2.205

2.  Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.

Authors:  Pamela Hummert; Teresa L Parsons; Laura M Ensign; Thuy Hoang; Mark A Marzinke
Journal:  J Pharm Biomed Anal       Date:  2018-02-08       Impact factor: 3.935

3.  Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic.

Authors:  Lizhi Zhao; Zhou Li; Zhen Zhou; Xiuyuan Kang; Baihuan Fang; Huan Ma; Qinghua Ge
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-04-05       Impact factor: 3.205

4.  An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.

Authors:  Deqing Xiao; Kah Hiing John Ling; Thomas Tarnowski; Sophia R Majeed; Polina German; Brian P Kearney; Yuwen Zhao; Yuan-Shek Chen; Lili Ma; Tianyi Zhang
Journal:  Anal Biochem       Date:  2020-02-05       Impact factor: 3.365

5.  Analysis of remifentanil with liquid chromatography-tandem mass spectrometry and an extensive stability investigation in EDTA whole blood and acidified EDTA plasma.

Authors:  Remco A Koster; Hugo E M Vereecke; Ben Greijdanus; Daan J Touw; Michel M R F Struys; Jan Willem C Alffenaar
Journal:  Anesth Analg       Date:  2015-06       Impact factor: 5.108

Review 6.  Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

Authors:  Erik De Clercq
Journal:  Biochem Pharmacol       Date:  2016-04-29       Impact factor: 5.858

7.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art.

Authors:  Karl Y Hostetler
Journal:  Antiviral Res       Date:  2009-05       Impact factor: 5.970

8.  Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.

Authors:  Joseph M Custodio; Marshall Fordyce; William Garner; Mona Vimal; Kah Hiing J Ling; Brian P Kearney; Srinivasan Ramanathan
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

9.  Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).

Authors:  Leah M Johnson; Sai Archana Krovi; Linying Li; Natalie Girouard; Zach R Demkovich; Daniel Myers; Ben Creelman; Ariane van der Straten
Journal:  Pharmaceutics       Date:  2019-07-04       Impact factor: 6.321

10.  Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.

Authors:  Jason J Schafer; Kaitlin N Sassa; Jaclyn R O'Connor; Ayako Shimada; Scott W Keith; Joseph A DeSimone
Journal:  Open Forum Infect Dis       Date:  2019-10-04       Impact factor: 3.835
View more
  3 in total

1.  Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Debbie Sanchez; Simon Webster; Amalia E Castonguay; Paul Webster; Christopher Buser; John A Moss; MyMy Trinh; Martin Beliveau; Craig W Hendrix; Mark A Marzinke; Michael Tuck; Richard M Caprioli; Michelle L Reyzer; Joseph Kuo; Philippe A Gallay; Marc M Baum
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

2.  Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis.

Authors:  Manjula Gunawardana; Mariana Remedios-Chan; Debbie Sanchez; Simon Webster; Patricia Galvan; Rob Fanter; Amalia E Castonguay; Paul Webster; John A Moss; Joseph Kuo; Philippe A Gallay; Kathleen L Vincent; Massoud Motamedi; Dana Weinberger; Mark A Marzinke; Craig W Hendrix; Marc M Baum
Journal:  Front Pharmacol       Date:  2020-11-25       Impact factor: 5.810

3.  Bioequivalence Evaluation of Two Formulations of Tenofovir Alafenamide Tablets in Healthy Subjects Under Fasting and Fed Conditions.

Authors:  Qiuying Li; Lihui Jia; Wenli Hu; Shu Dong; Chaohong Cai
Journal:  Drug Des Devel Ther       Date:  2021-06-16       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.